This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
CCXI Aperçu des actions
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
Score flocon de neige | |
---|---|
Évaluation | 2/6 |
Croissance future | 5/6 |
Performances passées | 0/6 |
Santé financière | 4/6 |
Dividendes | 0/6 |
ChemoCentryx, Inc. Concurrents
Historique des prix et performances
Historique des cours de bourse | |
---|---|
Prix actuel de l'action | US$51.99 |
Plus haut sur 52 semaines | US$52.00 |
Plus bas sur 52 semaines | US$14.95 |
Bêta | 1.23 |
1Variation sur 1 mois | 0.41% |
Variation sur 3 mois | 134.51% |
Variation sur 1 an | 50.39% |
3Variation sur 3 ans | 558.10% |
Variation sur 5 ans | 642.71% |
Évolution depuis l'introduction en bourse | 372.64% |
Nouvelles et mises à jour récentes
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Rendement pour les actionnaires
CCXI | US Biotechs | US Marché | |
---|---|---|---|
7D | 0.1% | 0.1% | 0.07% |
1Y | 50.4% | 14.0% | 22.7% |
Rendement vs Industrie: CCXI exceeded the US Biotechs industry which returned -1.9% over the past year.
Rendement vs marché: CCXI exceeded the US Market which returned -19.8% over the past year.
Volatilité des prix
CCXI volatility | |
---|---|
CCXI Average Weekly Movement | 31.3% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: CCXI's share price has been volatile over the past 3 months.
Volatilité au fil du temps: CCXI's weekly volatility has increased from 18% to 31% over the past year.
À propos de l'entreprise
Fondée | Salariés | PDG | Site web |
---|---|---|---|
1996 | 178 | n/a | www.chemocentryx.com |
ChemoCentryx, Inc. Résumé des fondamentaux
CCXI statistiques fondamentales | |
---|---|
Capitalisation boursière | US$3.74b |
Bénéfices(TTM) | -US$133.09m |
Recettes(TTM) | US$37.28m |
100.3x
Ratio P/S-28.1x
Ratio P/ELe site CCXI est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
CCXI compte de résultat (TTM) | |
---|---|
Recettes | US$37.28m |
Coût des recettes | US$71.86m |
Marge brute | -US$34.58m |
Autres dépenses | US$98.51m |
Les revenus | -US$133.09m |
Derniers bénéfices déclarés
Jun 30, 2022
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) | -1.85 |
Marge brute | -92.76% |
Marge bénéficiaire nette | -357.01% |
Ratio dettes/capitaux propres | 10.5% |
Quelles ont été les performances à long terme de CCXI?
Voir les performances historiques et les comparaisons